Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$9.26
+1.3%
$9.33
$5.45
$18.98
$306.65M1.9270,665 shs155,901 shs
InspireMD, Inc. stock logo
NSPR
InspireMD
$2.43
-0.2%
$2.42
$1.99
$3.80
$101.17M0.68102,402 shs25,529 shs
RxSight, Inc. stock logo
RXST
RxSight
$8.80
+1.1%
$9.03
$6.32
$57.53
$360.38M1.181.05 million shs724,262 shs
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$38.92
-2.1%
$37.08
$5.21
$46.58
$333.54M1.3951,597 shs25,123 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-0.11%+1.90%+1.67%-30.60%+15.40%
InspireMD, Inc. stock logo
NSPR
InspireMD
-0.41%-1.62%-9.67%-6.54%-11.64%
RxSight, Inc. stock logo
RXST
RxSight
-3.76%+2.35%+11.54%-42.99%-84.57%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-4.54%-5.33%+9.69%+47.22%+3,974,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
NeuroPace, Inc. stock logo
NPCE
NeuroPace
3.8443 of 5 stars
3.45.00.00.03.63.30.6
InspireMD, Inc. stock logo
NSPR
InspireMD
3.4134 of 5 stars
3.54.00.00.01.44.20.6
RxSight, Inc. stock logo
RXST
RxSight
2.2788 of 5 stars
3.03.00.00.02.41.70.6
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
2.3892 of 5 stars
3.50.00.00.02.82.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
NeuroPace, Inc. stock logo
NPCE
NeuroPace
2.83
Moderate Buy$16.6079.36% Upside
InspireMD, Inc. stock logo
NSPR
InspireMD
3.00
Buy$4.5085.57% Upside
RxSight, Inc. stock logo
RXST
RxSight
1.91
Reduce$10.0013.64% Upside
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
3.00
Buy$55.0041.32% Upside

Current Analyst Ratings Breakdown

Latest NSPR, RXST, SNWV, and NPCE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/3/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Northland Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$55.00
8/22/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$54.00 ➝ $55.00
8/13/2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/13/2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$17.00 ➝ $15.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$16.00 ➝ $8.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetHold ➝ Hold$9.00 ➝ $8.00
8/8/2025
RxSight, Inc. stock logo
RXST
RxSight
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$22.00 ➝ $11.00
7/29/2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$49.00
7/15/2025
RxSight, Inc. stock logo
RXST
RxSight
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$20.00 ➝ $9.00
7/10/2025
RxSight, Inc. stock logo
RXST
RxSight
Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Hold$24.00 ➝ $9.00
7/9/2025
RxSight, Inc. stock logo
RXST
RxSight
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetUnderperform ➝ Underperform$18.00 ➝ $9.00
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
NeuroPace, Inc. stock logo
NPCE
NeuroPace
$79.91M3.83N/AN/A$0.59 per share15.69
InspireMD, Inc. stock logo
NSPR
InspireMD
$7.07M14.32N/AN/A$1.83 per share1.33
RxSight, Inc. stock logo
RXST
RxSight
$139.93M2.57N/AN/A$6.79 per share1.30
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
$32.63M10.22N/AN/A($1.72) per share-22.63
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$27.14M-$0.84N/AN/AN/A-29.29%-168.61%-25.48%11/11/2025 (Estimated)
InspireMD, Inc. stock logo
NSPR
InspireMD
-$19.92M-$0.83N/AN/AN/A-413.96%-69.42%-57.68%N/A
RxSight, Inc. stock logo
RXST
RxSight
-$27.45M-$0.80N/AN/AN/A-21.93%-11.56%-10.31%11/6/2025 (Estimated)
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$31.37M-$8.25N/AN/A-97.03%N/A-135.15%N/A

Latest NSPR, RXST, SNWV, and NPCE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/12/2025Q2 2025
NeuroPace, Inc. stock logo
NPCE
NeuroPace
-$0.24-$0.26-$0.02-$0.26$23.08 million$23.52 million
8/8/2025Q2 2025
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
-$0.09$0.01+$0.10$0.01$10.14 million$10.16 million
8/7/2025Guidance Update
RxSight, Inc. stock logo
RXST
RxSight
-$0.04-$0.08-$0.04-$0.29$39.78 million$33.64 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
NeuroPace, Inc. stock logo
NPCE
NeuroPace
N/AN/AN/AN/AN/A
InspireMD, Inc. stock logo
NSPR
InspireMD
N/AN/AN/AN/AN/A
RxSight, Inc. stock logo
RXST
RxSight
N/AN/AN/AN/AN/A
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
NeuroPace, Inc. stock logo
NPCE
NeuroPace
3.02
5.47
4.51
InspireMD, Inc. stock logo
NSPR
InspireMD
N/A
6.39
6.05
RxSight, Inc. stock logo
RXST
RxSight
N/A
13.93
12.70
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
N/A
0.43
0.31

Institutional Ownership

CompanyInstitutional Ownership
NeuroPace, Inc. stock logo
NPCE
NeuroPace
78.83%
InspireMD, Inc. stock logo
NSPR
InspireMD
44.78%
RxSight, Inc. stock logo
RXST
RxSight
78.78%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
42.53%

Insider Ownership

CompanyInsider Ownership
NeuroPace, Inc. stock logo
NPCE
NeuroPace
20.50%
InspireMD, Inc. stock logo
NSPR
InspireMD
29.72%
RxSight, Inc. stock logo
RXST
RxSight
9.57%
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
14.90%
CompanyEmployeesShares OutstandingFree FloatOptionable
NeuroPace, Inc. stock logo
NPCE
NeuroPace
17033.08 million26.30 millionOptionable
InspireMD, Inc. stock logo
NSPR
InspireMD
5041.72 million18.33 millionOptionable
RxSight, Inc. stock logo
RXST
RxSight
22040.92 million37.00 millionOptionable
Sanuwave Health Inc. stock logo
SNWV
Sanuwave Health
408.57 million7.29 millionN/A

Recent News About These Companies

Sanuwave Health (NASDAQ:SNWV) Upgraded to Strong-Buy at Wall Street Zen
Sanuwave (SNWV) Q2 Revenue Jumps 42%
Sanuwave Announces Q2 FY2025 Financial Results
SANUWAVE Health, Inc. (SNWV): A Bull Case Theory
Sanuwave Announces Q1 FY2025 Financial Results

New MarketBeat Followers Over Time

Media Sentiment Over Time

NeuroPace stock logo

NeuroPace NASDAQ:NPCE

$9.26 +0.12 (+1.26%)
As of 03:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.

InspireMD stock logo

InspireMD NYSE:NSPR

$2.42 -0.01 (-0.21%)
As of 03:25 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions. InspireMD, Inc. has a strategic agreement with Jacobs Institute to execute an early feasibility study of CGuard Prime for the treatment of acute stroke patients with tandem lesions. The company sells its products through local distribution partners. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

RxSight stock logo

RxSight NASDAQ:RXST

$8.80 +0.10 (+1.15%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.

Sanuwave Health stock logo

Sanuwave Health NASDAQ:SNWV

$38.92 -0.83 (-2.09%)
As of 02:55 PM Eastern

SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, and musculoskeletal and vascular structures. The company's lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body's normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.